Peptide antigens are being developed and utilized to serologically diagnose infectious diseases. Detection of antibodies specific to a pathogen by ELISA technology is one way researchers identify exposure to an infectious disease agent. Mimicking immunodominant epitopes found on viral, bacterial and parasitic proteins, peptide antigens offer a more specific and standardizable antigen reagent than native sources. Antibodies associated with a wide variety of infectious agents have been detected using peptide antigens.
Peptide antigens can also be employed as molecular probes to measure antibody in infectious disease serology. Serologic assays containing whole microbes can employ hundreds of epitopes that may cross-react with antibodies to closely related microbes. In contrast, peptides can be selectively used to detect antibodies that will only bind to antigens from a single microbe. Peptides are frequently employed when testing sera if clinicians require a high level of specificity to know exactly which infectious agent a patient was exposed to. This could include distinguishing whether a patient is currently infected or has antibodies from clearing a previous infection.
The principle of antibody testing is used in many ELISA tests for infectious diseases. If someone becomes exposed to a disease-causing microbe, their body's immune system will create antibodies specific for that microbe. Antibodies created from exposure by the adaptive immune system can persist for years after infection in the bloodstream. Since we can test for antibodies rather than for the pathogen itself, ELISA can detect whether someone has been exposed to an infectious disease by binding an antigen for a specific antibody.
Fig. 1 Schematic representation of laboratory tests for determining evidence of infection with FMDV after an outbreak in FMD-free countries with or without vaccination and FMD endemic countries.1,5
Peptide antigens are commonly used serologically because they can be chosen to represent exact epitopes and are easy to standardize. Any sequence defined as immunodominant by epitope mapping can be synthesized exactly without additional protein sequences that could cause cross-reactivity. They are especially useful for discrimination between antigens of closely related microbes or serotypes because unique signature sequences can be targeted.
Table 1 Characteristics of Antigen Formats in Infectious Disease Serology
| Characteristic | Synthetic Peptide Antigens | Recombinant Protein Antigens |
| Epitope specificity | Defined linear sequences | Conformational and linear determinants |
| Production complexity | Chemical synthesis | Heterologous expression systems |
| Batch consistency | High reproducibility | Variable post-translational modifications |
| Cross-reactivity potential | Minimized shared epitopes | Broad antigenic representation |
| Customization capability | Rapid sequence modification | Limited by expression constraints |
Peptides have benefits over recombinant proteins, such as greater batch-to-batch homogeneity and lack of contaminants from expression systems. Peptides are chemically synthesized and thus avoid the variation introduced when using cells to produce antigens. Peptides can also include unnatural amino acids or amino acids that have been modified to resemble post-translational changes, which allows inclusion of antibody specificities that may not be present or correctly included when using recombinant antigens.
Factors that impact peptide antigen design for ELISA include sensitivity and specificity requirements of the assay itself. Assays should be sensitive enough to detect antibodies at lower concentrations than would typically be present early on in infection. Assays should also be specific enough that cross reactivity does not occur with antibodies targeting similar infections. Other challenges with peptide antigens include variability of individuals' immune response to specific epitopes, as well as variability in coating antigens consistently and uniformly from assay to assay.
Identification of antibodies early in infection can be problematic for peptide ELISAs. During the time that you want to treat patients, the level of antibodies circulating in the body may be too low to detect. Patients sometimes begin to make antibodies early during infection. Other patients may not make antibodies until later. Therefore, you want your ELISA to detect antibodies even if they have low affinity for your peptide. If your peptide is too short, it may not be recognized by low affinity antibodies for the target antigen, creating a false negative.
Cross-reactions with antigens from other organisms that are closely related is another specificity issue that frequently arises when peptides contain sequences that are conserved across several species. Antibodies to linear epitopes that are shared by several pathogens of the same genus or family will give rise to cross-reactive signals that are indistinguishable serologically. This can be particularly troublesome in diseases where there are multiple infections endemic to similar regions. Accounting for antigenic diversity found between circulating strains of pathogenic microbes can be challenging if changes to epitopes maintain sequence homology with other pathogens.
An infected individual's immune system may recognize different epitopes due to genetic differences, previous exposure history, and stage of disease during sampling. Antibody responses are polyclonal and may target different areas of an antigen between individuals; some epitopes may be dominant and others may not elicit an antibody response at all. Peptide design must account for these differences as a peptide that works well in one group of patients may not detect antibodies that recognize a different epitope. Additionally, conformational epitopes tend to dominate natural antibody responses to infections, reducing the likelihood that linear epitopes will be recognized by antibodies.
A significant issue facing commercialization of peptide-based ELISA assays is manufacturing consistency. As both sensitivity and consistency of an ELISA depends on how much antigen is coated onto the well surface and how that antigen is oriented, variability in these parameters between production lots of an ELISA kit will affect test reproducibility. Peptide structure and characteristics can vary when scaling up production from one-of production to routine production batches. A change in peptide purity or solubility from kit to kit can cause variability in immobilization efficiency on the well surface, which will be reflected in assay signal. Peptide conformation and exposure may also be affected by other variables such as incubation temperature, humidity, and coating buffer. Both of these issues have implications in the reproducibility of an assay over time, and thus test consistency, especially when monitoring disease progression or serum markers longitudinally. The production processes should be tightly controlled between kits to ensure batch-to-batch reproducibility.
The peptides that are chosen as epitopes play an important role in how effective a diagnostic assay will be. They should be able to be recognized by antibodies and elicit an immune response. Peptides should also not cross react with other antigens. To choose peptides, one must look at the protein structure of the antigen and identify regions of the pathogen that can potentially be antigenic and draw an immune response. They should not be homologous to human proteins. Care should also be taken to account for antigenic variability. Ideally you want your peptides to cover all strains of the pathogen. Peptides that are too short may not be antigenic and some peptides may have a propensity to fold which may or may not be useful in a solid phase assay.
Table 2 Strategic Considerations for Peptide Epitope Selection in Infectious Disease Assays
| Selection Criterion | Strategic Objective | Practical Implication |
| Immunodominance | Target regions with robust antibody recognition | Enhanced diagnostic sensitivity across diverse patient populations |
| Conservation balance | Capture common epitopes while allowing strain discrimination | Broad coverage without loss of specificity |
| Host homology avoidance | Minimize similarity to human proteins | Reduced risk of autoimmune cross-reactivity |
| Structural properties | Optimize for aqueous accessibility and stability | Reliable solid-phase presentation and storage |
Linear epitopes can be dominant epitopes. Dominant epitopes are the parts of the antigen that are recognized most frequently by immune cells (such as B cells). More specifically, immunodominant linear epitopes are regions on proteins (typically pathogens) that are most commonly recognized by antibodies during an immune response (specifically a natural immune response). They are found by mapping humoral immune responses to overlapping peptides, or computationally predicting epitopes based on surface accessibility, hydrophilicity, etc. Linear epitopes are useful epitopes to target when creating diagnostic tools because they can easily be manufactured. In contrast to conformational epitopes, linear epitopes can be made using pure synthetically created peptides that will be identical in every production batch. When mapping immunodominant epitopes one should be careful to select epitopes that not only bind antibodies, but are protective (immunodominant), as opposed to epitopes that weakly bind antibodies (subdominant epitopes).
Determining whether an epitope should be conserved among different strains of the organism, or strain-specific, is another key question when selecting epitopes for infectious diseases. Conserved sequences across multiple strains could allow detection of multiple strains with one peptide whereas strain-specific sequences could be used to detect differences between strains of similar microbes. Ideally, both features would be used when designing peptide-based diagnostics. If the goal is to detect any possible strain of an infectious agent, then highly conserved sequences should be used. On the other hand, if it matters to know the exact strain of the infectious agent then less conserved sequences should be utilized. For highly prevalent diseases that have multiple different strains co-circulating at the same time (such as influenza), it is important to know which strains are co-circulating so that the most conserved sequences between those strains can be used. Sequence databases should be constantly referenced to ensure that variants used to detect the pathogen are still found in strains circulating in the population.
One parameter often used for ensuring safety in infectious disease assays is to screen out peptides that are homologous to peptides found in humans. When designing vaccines or assays with peptides from pathogen proteins that resemble peptides from human proteins, there is risk that the antibody response will cause autoimmunity or cross-react with assays targeting the similar self-peptide. Alignments against the human proteome can be used to identify regions of similarity to human proteins and remove them from vaccines/screens.
The ideal peptide would range between 15-40 amino acids in length. This allows enough amino acids to allow for a full epitope to be formed that B-cells can recognize, but is short enough that the peptide can be chemically synthesized and remain water soluble. Shorter peptides will either be too short to form a single antigenic determinant or will not maintain a fixed shape. Longer peptides are harder to synthesize and may have regions that are recognized by other antibodies, making them cross-reactive. Peptides that are random coils and lie on the surface of the protein are more antigenic. Side chains that are hydrophilic help to keep the peptide-water soluble. Flexible linkers between the peptide and the point of attachment to the surface can help minimize interference from the surface.
The method of immobilization used affects ELISA assays significantly. Peptides can be adsorbed to plates through hydrophobic interaction or electrostatic interactions, also known as passive adsorption, or can be immobilized using antibodies with specific affinity to the antigen or antibody of interest, also known as active immobilization. Passive adsorption is a simpler method than antibody capture but may not hold the antigen as well to the surface and there is the possibility that some of the antigen may be lost in the washing steps. Antibody capture can be a more involved process but immobilizes the antigen of interest very well to the surface. Decide which method is best suited for your peptide, the antibodies you have available, and what you are using it for clinically.
Antigen adsorption to plates coated with modified polystyrene works through physical forces between amino acids sequences of peptides and the surface of the modified polystyrene matrix. Plates designed for high binding capture commonly known as HiBind plates have been irradiated to form carboxyl and hydroxyl groups that make it more hydrophilic than regular polystyrene plates. Peptides with short sequences suffer from this immobilization method because they often lack hydrophobic regions large enough to anchor the peptide. Additionally, when peptides bind to plastic they can lay flat in a random manner that hides the epitope. Peptides attached by only physical forces can also easily wash off the plate causing lower reproducibility and fewer active peptides available for antibodies to bind.
One method that addresses these concerns utilizes biotinylated peptides and streptavidin-coated surfaces for immobilization. This interaction is highly-affinity, allowing site-directed immobilization through terminal biotinylation of the peptide allowing optimal orientation with respect to the surface. With biotin-streptavidin binding, sequences that would otherwise be inaccessible to antibody recognition are surface exposed. Additionally, because streptavidin is a multimeric protein, high surface density can be achieved. This can improve binding stability during assay conditions. Site-directed immobilization of antigens can be critical when analyzing samples with low-affinity antibodies or crude biological samples where stability of antigen presentation is key to assay reproducibility.
Epitope density and orientation influence how well the epitopes are exposed to antibodies in solution. Epitopes that are displayed by anchored peptides may be inaccessible to their target antibodies even though they are presented on the solid phase. If peptides are randomly attached to the solid surface, epitopes may be physically buried against the surface or within aggregates of molecules, preventing antibodies from binding. Site-specific immobilization or spacers tether peptides away from the surface and allow for a more natural flexibility, allowing antibodies to bind. Orientation control allows for antibodies that recognize conformational epitopes to bind.
Optimization efforts when developing peptide ELISAs are also focused on lowering background signals. Background signal can arise when proteins within the serum non-specifically bind to the solid phase during the assay causing "noise" that makes specific antibody binding more difficult to detect. The utilization of biotin-streptavidin technology lends itself to decreased background since only molecules with the correct structure will bind. This eliminates proteins from interfering that will bind non-specifically to hydrophobic surfaces. Other methods used to decrease background signal include the use of protein-based blocking solutions, limiting exposure to non-ionic detergents, and thorough washing.
Advantages of biotinylated peptides include their use in the creation of immunosorbent assays for infectious diseases. Immobilization of biotinylated peptides can be oriented due to the interaction between biotin and streptavidin, leading to increased affinity over passive adsorption to plastic because the orientation allows for immobilization of only regions of the peptide designed to interact with the analyte. This technique allows for consistent immobilization of antigens for diagnostic assays, such as those needed to diagnose infectious diseases. Consistent immobilization allows for early detection of antibodies specific to an infectious agent when concentrations of antibodies may be low. Using biotinylated peptides can also decrease nonspecific binding events often observed with complex samples.
Antigens adsorbed to streptavidin coated microplates are directionally immobilized through their interaction with biotin. This constrains the orientation of peptide antigens to the favorable relative orientation instead of random orientations associated with passive adsorption. Additionally, when the biotinylation site is introduced at termini of the peptide that is separated from the antigenic sequence by hydrophilic linkers, immunodominant epitopes are displayed outward, into solution, rather than against the plate surface as often occurs with passive adsorption where peptide antigens with hydrophobic sequences non-specifically adsorb to the polystyrene plate. This allows epitopes to be sterically accessible for antibody binding, increasing detection of antigen-specific antibodies and minimizing false negative results due to epitope inaccessibility.
Detection sensitivity is increased by use of biotin-streptavidin. As streptavidin is a tetramer, it presents four binding sites for biotin. Antibodies are present at low levels, so amplification via multiple biotin-streptavidin complexes allows more detection signal from fewer antibodies. This allows low levels of antibodies to be detected, such as those present early in an infection, before they have reached levels detectable by other methods. Weak antigen-antibody complexes will not dissociate during washing due to the strong biotin-streptavidin interaction. Early detection can allow an infection to be treated before the disease has progressed too far.
The great advantage of the high affinity of biotin to streptavidin is the low background signal usually observed when assaying serum or plasma. Passive adsorption will cause many proteins found in serum to bind to your strip via hydrophobic forces. By using this technique you are only binding your antibody of interest and avoiding non-specific immunoglobulins and complement proteins. This minimizes background thus allowing a clearer differentiation between positive and negative samples. This can be especially helpful when assaying samples from patients with low antibodies present or samples with large amounts of interfering substances that may produce background in other assay types.
Use of generic biotinylation chemistry and strong streptavidin surfaces allows uniform coating of antigens between lots and plates. This consistency circumvents lot-to-lot and well-to-well variation associated with passive adsorption of antigens to plates, where minute changes in coating conditions can change antigen density and orientation. This increased consistency allows for quality control during manufacture providing the reproducibility required for epidemiologic studies and screening programs looking for serologic patterns due to pathogens rather than process variation.
Peptide antigens used in infectious disease diagnostics require careful analytical characterization and standardized production processes in order to obtain reproducible assay results between batches and uses. Synthetic peptides that are used as diagnostic reagents must adhere to strict quality control measures for chemical purity, conformation, and potency to ensure proper detection of antigen-specific antibodies. Factors involved in the production process include considerations for synthetic routes, characterization techniques, documentation, and upscaling, all of which contribute to the final quality of peptides for diagnostic use.
Fig.2 Laboratory and clinical tests for the detection of influenza virus.2,5
Peptide purity can be important for the specificity of diagnostic assays. Signal intensity of both specific and nonspecific binding may be affected by peptide impurities. During synthesis, deletion products, residual side chain protecting groups and other truncated impurities can compete with your peptide for antibody binding or cause nonspecific signal if used in complex samples. Higher purity can prevent antibodies from recognizing epitopes other than those presented by the target pathogen. The required purity can depend on the desired diagnostic use. A purity that is acceptable for qualitative diagnostic applications may not be sufficient for quantitative or clinical diagnostics where more stringent purity may be required for accurate diagnosis and monitoring of infection.
Peptide identity, purity and correct structure are usually validated before shipping. High-performance liquid chromatography (HPLC) separation of peptides based on hydrophobicity will often allow one to separate the intended sequence from synthetic contaminants. Mass spectrometry can then be used to detect the peptide and its correct molecular weight. Peptide sequencing using tandem mass spectrometry can also be used to confirm the identity of the synthesized peptide to ensure that the correct antigen sequence has been produced. Taken together, these orthogonal techniques can be used to assure the specificity and correctness of antigens, allowing one to generate data needed for regulatory submissions/CL compliance/QA documentation, and process validation/release throughout manufacturing.
Batch Traceability and Complete Documentation must be robust aspects of the antigen quality control process. All lots of antigens must have associated documentation including the materials used to start the antigen synthesis, the synthesis procedure, purification conditions, antigen testing data, and stability information. If there is a problem with antigen performance it may be possible to track back through these documents to identify possible causes. Furthermore, this information allows you to prove to regulatory agencies that you have well controlled processes for manufacturing your IVD antigen. Documentation such as design history file, batch records, and certificate of analysis allows for lots of antigens to be traceable all the way back to their origins and through their use in kits.
Scaling peptide production from research quantities to industrial scale is a challenge that must be met with manufacturing optimization that does not sacrifice analytical integrity. Optimized peptide synthetic methods need to consider the transition from laboratory scale solid-phase synthesis reactors to larger capacity reactors and resin loadings while not sacrificing coupling efficiency or purification metrics. Validating that these scaled-up reactions provide equivalent product as laboratory scale reactions is key. Consideration should also be given to streamlining and automating synthesis and purification methods to decrease human error and the need for analytical chemicals like amino acid derivatives. The reliable supply of these raw materials will also need to be established. Once optimized and validated, large quantities of antigen can be produced for use in diagnostic kits. These kits can then be distributed to meet the demands of the population and provide broad access to quality infectious disease testing.
Random coating, in contrast to physical adsorption of biotinylated peptides, involves incubating microplates directly with the antigen of interest to be adsorbed onto the wells via hydrophobic forces. This can cause unwanted changes to the conformation of the antigen and possible unpredictable display of epitopes. Physical adsorption of biotinylated peptides allows site directed binding of antigens to plastic surfaces with high affinity molecules such as streptavidin, avoiding potential detrimental changes in antigen conformation. Benefits include higher sensitivity, lower background, and better lot-to-lot reproducibility as compared to random coating. Oriented immobilization allows for more efficient detection of antibodies of low concentrations without producing unwanted background.
Table 3 Comparative Analysis of Immobilization Strategies in Infectious Disease ELISA
| Performance Parameter | Biotinylated Peptide Immobilization | Direct Coating Methodology |
| Antigen orientation | Uniform, site-specific presentation | Random, uncontrolled attachment |
| Binding stability | High resistance to dissociation | Susceptible to leaching during washing |
| Background generation | Minimal non-specific protein adherence | Elevated hydrophobic interactions |
| Manufacturing consistency | High batch-to-batch reproducibility | Variable due to coating condition sensitivity |
| Detection capability | Enhanced for low-affinity antibodies | Limited by epitope accessibility |
The ability to capture even low amounts of antibody is another advantage of immobilization techniques. During the early stages of infection, the antibody response may not be well developed. Using biotinylated peptides takes advantage of streptavidin's four binding sites for biotin allowing for a higher antigen density that cannot be washed away. Weakly-binding antibodies that are present during early seroconversion may be lost using direct coating methods because antibodies can fall off the plate if they don't bind tightly to the antigen, and some antigens change conformation when adsorbed to the plastic surface. Also, since the antigen is oriented the binding sites will be available to bind the antibodies.
Non-specific binding and background interference are problems that are affected differently by the assay immobilization technique used. With direct coating, proteins and antibodies that are not specific for the pathogen of interest from serum will non-specifically stick to the polystyrene well surface, contributing to higher background absorbance readings. On the other hand, because the biotin-streptavidin interaction is so specific, it will only capture specific targets and exclude other proteins found in serum. Additionally, because the target is oriented, there are fewer antigen dimers where non-specific proteins can get caught. Cross-reactivity can also occur independently from the assay immobilization strategy as it results from similar epitope amino acid sequences in different antigens. However, because there is less background with the biotin-streptavidin assay, it is easier to distinguish from positives.
A critical aspect to consideration for clinical use is batch-to-batch consistency and long-term assay stability, both of which are highly dependent on the immobilization method selected. Immobilization via biotinylated peptides offers high reproducibility due to controlled conjugation chemistry and high-affinity binding that is insensitive to environmental or wash conditions. Biotinylation provides a standard level of peptide density on each well surface, whereas coating conditions can vary slightly well-to-well based on concentration of coating buffer, temperature, and drying process thus changing surface density of the antigen. Biotinylated peptides offer consistent batch-to-batch performance allowing for multi-center diagnostic standardization as well as lack of drift for repeated testing of patients over time.
Infectious disease ELISA assays often require high analytical sensitivity, precise epitope presentation, and consistent antigen performance across production batches. Custom biotinylated peptide solutions provide a controlled immobilization strategy that enhances antigen orientation and reproducibility compared to passive adsorption alone. By integrating rational epitope design, validated conjugation chemistry, and standardized manufacturing workflows, biotinylated peptides can be tailored to support reliable antibody detection in serological assay development.
Accurate antibody recognition depends on preserving immunodominant regions within the peptide sequence. Site-specific biotinylation allows controlled placement of the biotin moiety at the N-terminus, C-terminus, or selected internal residues based on sequence analysis and known epitope regions. This targeted labeling minimizes the risk of altering antibody-binding sites and supports predictable orientation upon capture by streptavidin-coated surfaces. Directional immobilization helps improve epitope accessibility and contributes to more consistent binding efficiency in ELISA workflows.
Steric hindrance between the immobilized peptide and the solid surface can limit antibody access, particularly for short linear epitopes commonly used in infectious disease assays. Incorporating spacer elements such as aminohexanoic acid (Ahx) or polyethylene glycol (PEG) linkers increases the distance between the peptide and the plate surface. Proper spacer design enhances conformational flexibility and reduces surface constraints, which may improve signal intensity and reduce variability. Spacer length and composition are selected according to peptide size and assay configuration to optimize antigen presentation.
Peptide purity directly affects assay specificity and background performance. Custom biotinylated peptides are purified using high-performance liquid chromatography (HPLC) to meet defined purity specifications suitable for diagnostic assay development. Molecular identity and successful biotin incorporation are confirmed through liquid chromatography-mass spectrometry (LC-MS). Clearly defined analytical criteria help ensure structural accuracy, reduce the presence of synthesis-related impurities, and support reproducible coating behavior across batches.
Infectious disease ELISA development typically progresses from early feasibility studies to routine production. A scalable manufacturing platform enables consistent synthesis from small research quantities to larger production volumes without altering product specifications. Standardized synthesis parameters, controlled conjugation conditions, and documented batch traceability support reliable lot-to-lot consistency. This structured production approach helps maintain stable antigen performance and dependable supply throughout ongoing assay development and manufacturing cycles.
Synthetic peptides allow precise targeting of immunodominant linear epitopes from pathogen proteins. They offer high sequence specificity, reduced cross-reactivity compared to full-length proteins, and consistent batch quality due to controlled chemical synthesis.
Cross-reactivity can be reduced by selecting pathogen-specific regions with low homology to other microorganisms or host proteins. Sequence alignment analysis and careful epitope selection are critical steps during assay development.
Yes. Peptide length affects structural flexibility, adsorption behavior, and epitope exposure. Short peptides may require optimized immobilization strategies, such as spacer incorporation or directional capture systems, to enhance antibody accessibility.
Biotinylation is not always required, but it can improve orientation and reproducibility in cases where passive adsorption results in weak or variable signals. Directional immobilization may enhance assay consistency, especially in sensitivity-critical formats.
Weak signals may result from insufficient coating concentration, poor epitope exposure, peptide aggregation, or suboptimal buffer conditions. Optimization of immobilization strategy, coating parameters, and blocking conditions can improve signal strength.
References
